| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司是一家集医药研发、生产制造、销售等业务于一体的多元化、专业化医药集团上市公司，公司秉承“以奋斗之心、与生命同行”之理念，始终以客户需求为导向，致力于为客户提供创新特色专科领域的药物产品。公司拥有覆盖麻醉产品、肠外营养系、肿瘤止吐、肝胆消化、抗生素、心脑血管等多个细分领域的产品布局，现有46个品种多为国内首家或独家仿制，主要产品包括创新药环泊酚注射液、甲磺酸多拉司琼注射液、多烯磷脂酰胆碱注射液、氟哌噻吨美利曲辛片、注射用甲泼尼龙琥珀酸钠等。 公司集新药研发、生产制造、推广营销业务于一体的多元化，专业化医药集团，致力于成为最受信赖的国际化制药企业。公司以“创新”为内核，凭借行业领先的综合创新实力，获得行业高度认可，连续3年荣获中国创新力医药企业，先后入选2021年度中国化药企业TOP100、2021年福布斯中国最具创新力企业TOP50榜，中国医药工业百强系列榜单，医药自主创新先锋企业、医药商业百强及医药行业守法诚信企业，获评制药行业企业信用等级AAA。 公司首个自主研发的1.1类创新静脉麻醉药，环泊酚注射液已在中国获批上市，为中国首个自主研发且具有全球自主知识产权的1类创新药。在上市第一年2021年通过国家医保谈判进入新版目录。上市2年，获得国内临床高度认可，市场份额已经在同类市场的Top3。同时开启了该药的国际化进程，目前“海思科国际”在美国开展的麻醉药HSK3486（环泊酚注射液）的三期临床试验正在顺利推进，有望未来2年在美国上市。 公司糖尿病周围神经痛药物HSK16149和2型糖尿病治疗药物HSK7653已申报NDA，正在审评中。两个创新药的三期临床数据，同时入围2023年美国糖尿病年会（ADA）口头报告，国际对海思科创新产品给予高度认可。 | ||||||||||||||||||||||||
| Main Business | 集新药研发、生产制造、推广营销业务于一体的多元化、专业化医药集团。 | ||||||||||||||||||||||||
| Legal Representative | 范秀莲 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 王萌 | ||||||||||||||||||||||||
| Solicitors | 北京市中伦律师事务所 | ||||||||||||||||||||||||
| Auditors | 信永中和会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0893-7834865;028-67250551 | ||||||||||||||||||||||||
| Fax No | 0893-7661674;028-67250553 | ||||||||||||||||||||||||
| Website | www.haisco.com | ||||||||||||||||||||||||
| haisco@haisco.com;wangm@haisco.com;guoy@haisco.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 17/01/2012 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.270 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.200 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 3.752 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 18.453B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |